PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.

Yi QinQiangsheng HuJin XuShunrong JiWeixing DaiWensheng LiuWenyan XuQiqing SunZheng ZhangQuanxing NiBo ZhangXian-Jun YuXiaowu Xu

Published in: Cell communication and signaling : CCS (2019)

The present study demonstrated that PRMT5 epigenetically silenced the expression of the tumor suppressor FBW7, leading to increased cMyc levels and the subsequent enhancement of the proliferation of and aerobic glycolysis in pancreatic cancer cells. The PRMT5/FBW7/cMyc axis could be a potential therapeutic target for the treatment of pancreatic cancer.

Keyphrases

poor prognosis
signaling pathway
binding protein
combination therapy